Related Experiment Video
Updated: May 28, 2026
07:53
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
Synchronous lung cancers: when same histological types feature different molecular profiles and response phenotypes.
Giulia M Stella1, Francesca Cemmi, Simona Inghilleri
1Department of Hematological, Pneumological and Cardiovascular Sciences - Section of Pneumology, University and Fondazione IRCCS Policlinico San Matteo 27100 Pavia, Italy.
Journal of Cancer
|October 8, 2011
Summary
Synchronous bilateral lung cancers with different EGFR mutations responded differently to targeted therapy. Molecular profiling of cytology specimens is crucial for accurate diagnosis and treatment guidance.
Area of Science:
- Oncology
- Molecular Biology
- Pulmonology
Background:
- Synchronous bilateral lung cancers present diagnostic and therapeutic challenges.
- Histological similarity can mask underlying molecular heterogeneity.
- Epidermal Growth Factor Receptor (EGFR) mutations are key targets in non-small cell lung cancer.
Observation:
- A case of synchronous bilateral lung cancers with identical histology but distinct EGFR mutational status was analyzed.
- CT-guided fine needle aspiration was used for both histological and molecular characterization.
- Initial chemotherapy proved ineffective for both lesions.
Findings:
- The EGFR-mutated lung cancer demonstrated significant reduction (>50%) with Erlotinib treatment.
- The EGFR wild-type lung cancer showed only a minimal response to Erlotinib.
- Treatment response directly correlated with EGFR mutational status, validating molecular profiling.
Implications:
- Extensive molecular profiling is essential for multiple synchronous tumors to understand lesion associations.
- Molecular analysis of cytology specimens offers a safe and accurate diagnostic approach.
- Personalized therapy based on molecular profiles can optimize treatment outcomes for multifocal lung cancers.
Keywords:
synchronous bilateral lung cancerRelated Concept Videos
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...